Connect with us


Penny Stocks To Buy In May? 3 To Watch Before Next Week

Penny Stocks to Buy? Here are a few for your watch list.
The post Penny Stocks To Buy In May? 3 To Watch Before Next Week appeared first on Penny Stocks…



If you’re looking for penny stocks to buy, this market offers incredible opportunities. With how stock market volatility has been this month, a fast hand and a keen eye are crucial. When they say that this is a stock picker’s market, “they” most likely mean it’s a day trader’s market.

That’s because the trends have changed daily. With CPI and PPI data officially out, however, investors have some semblance of the state of inflation and a potential idea of what’s to come later this year.

Nevertheless, with the stock market gapping up on Friday, bulls are hopeful that the worst is behind them and that an interim “bottom” is in (until the next Fed-fueled bout of volatility comes to light). Today we look at some of the more beaten down penny stocks to buy according to retail traders. They’ve come under pressure along with the broader markets. However, with the turnaround in the broader markets, it will be interesting to see how the traders respond next week.

Penny Stocks To Buy?

  1. Vroom Inc. (NASDAQ: VRM)
  2. Ginkgo Bioworks Holdings Inc. (NYSE: DNA)
  3. Hycroft Mining Holding Corp. (NASDAQ: HYMC)

Finding The Best Penny Stocks To Buy

How do you find the best penny stocks to buy? Research, research, research. Conducting strong due diligence and pairing that with a core strategy will help you find the best penny stocks to buy regardless of your market conditions. Remember that “best” doesn’t always mean high volume, hundred percent returning stocks. In volatile environments, aiming for base hits instead of home runs may be better suited at the time. Today’s list of penny stocks has a few companies that have pulled an about-face as bulls have come back in control (for now). Are they the best penny stocks to buy before next week? That’s what I’ll leave you to decide.

1. Vroom Inc. (NASDAQ: VRM)

One of the most active penny stocks this week has been Vroom Inc. Shares of VRM stock have experienced some of the highest daily trading volumes in its history of being a public company. More than 250 million shares have exchanged hands this week following its latest earnings report. The used vehicle trading platform drove over $900 million in sales fur the first quarter. This beat Wall Street estimates of just under $880 million. The company’s loss per share of $0.71 was also better than expected. Wall Street’s consensus was for Vroom to post a loss of $1.01 per share for the quarter.

Thomas Shortt, Chief Executive Officer of Vroom, also commented, “As we look forward, we intend to prioritize unit economics over growth, reduce operating expenses, and focus on 4 key initiatives to build a profitable business. I would like to thank all of our Vroommates and our third-party partners for their support in serving our customers. I’m excited about the future for Vroom and look forward to sharing more on our long term vision with you at our upcoming investor event on May 26th.”

This year the company is focused on “unit economics,” according to CFO Robert Krakowiak. He sees immediate benefits stemming from Vroom’s acquisition of United Auto Credit Corporation and thinks the company is uniquely positioned to reduce operating expenses to accelerate its path to profitability. VRM stock has bounced back above $1.60 for the second time this week.

What to Know About Buying Penny Stocks on May 13th

2. Ginkgo Bioworks Holdings Inc. (NYSE: DNA)

Biotech is another one of the stock market sectors that has gotten beaten up lately. If you look at the Nasdaq Biotech ETF (NASDAQ: IBB), you’ll see what I mean. The ETF was rocked amid the broader market sell-off this month, taking it to some of the lowest levels since the 2020 pandemic. Needless to say, some investors have seen this as an opportunity, with a few biotech penny stocks responding accordingly.

Ginkgo Bioworks is one of these biotech penny stocks bouncing back this week. After hitting new lows of $2.09 on Thursday, DNA stock bounced above the $2.60 level on May 13th. The company’s focus on cell programming has placed it in the focus of traders looking for applications in the food industry. Ginkgo’s platform allows applications in food and agriculture, including the recent acquisition of Bayer’s West Sacramento Biologics R&D site.

Last month, the company announced the move to expand its platform capabilities. As the world’s food supply chain has gotten upended thanks to the Russia/Ukraine conflict, food and agriculture stocks have gotten some play. This week was also pivotal for the company as it made its way into the animal-free egg product category. Along with Evo Foods, Ginkgo Bioworks plans to develop animal-free egg proteins in Evo’s product portfolio.

DNA stock could also be on the radar for traders speculating on earnings trades. On Monday, May 16th, the company will report its first-quarter 2022 results. If DNA is on your list of penny stocks right now, keep this in mind.

penny stocks to buy Ginkgo Bioworks DNA stock chart

3. Hycroft Mining Holding Corp. (NASDAQ: HYMC)

Newly minted meme stock, Hycroft Mining, has come back into focus as bulls have regained control of stocks early on Friday. The company garnered the interest of the AMC Entertainment (NYSE: AMC) community of traders after the entertainment company invested in Hycroft. Plugging its ability to breed liquidity, AMC management justified its move in helping start-up stage companies.

Hycroft has also garnered some attention from mining stock investors this year. The company reported first-quarter production results earlier in May. Hycroft said it produced over 5,300 ounces of gold and more than 16,800 ounces of silver. While this was in line with forecasts, Hycroft management also discussed its strong cash position at the end of Q1. The company had over $172 million following its capital-raising efforts, including AMC Entertainment.

Despite posting a wider net loss, financials seem to have come secondary to the speculative hype thanks to retail traders. HYMC stock has bounced hack another 8% during Friday’s early session, and bullish optimism seems to have come back into the stock market today.

penny stocks to buy Hycroft Mining HYMC stock chart

Time To Buy Penny Stocks?

Is it time to buy penny stocks? Given that the “risk-on” approach to trading this quarter has been less prominent, higher volatility investments have taken a back seat for some. Depending on your risk tolerance, you can determine if it’s time to buy penny stocks in May or wait a little longer for a confirmed uptrend. On the other hand, if you know how to trade penny stocks, then this price fluctuation is music to your ears.

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!

The post Penny Stocks To Buy In May? 3 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information |

Read More

Continue Reading


Repeated COVID-19 Vaccination Weakens Immune System: Study

Repeated COVID-19 Vaccination Weakens Immune System: Study

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Repeated COVID-19…



Repeated COVID-19 Vaccination Weakens Immune System: Study

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Repeated COVID-19 vaccination weakens the immune system, potentially making people susceptible to life-threatening conditions such as cancer, according to a new study.

A man is given a COVID-19 vaccine in Chelsea, Mass., on Feb. 16, 2021. (Joseph Prezioso/AFP via Getty Images)

Multiple doses of the Pfizer or Moderna COVID-19 vaccines lead to higher levels of antibodies called IgG4, which can provide a protective effect. But a growing body of evidence indicates that the “abnormally high levels” of the immunoglobulin subclass actually make the immune system more susceptible to the COVID-19 spike protein in the vaccines, researchers said in the paper.

They pointed to experiments performed on mice that found multiple boosters on top of the initial COVID-19 vaccination “significantly decreased” protection against both the Delta and Omicron virus variants and testing that found a spike in IgG4 levels after repeat Pfizer vaccination, suggesting immune exhaustion.

Studies have detected higher levels of IgG4 in people who died with COVID-19 when compared to those who recovered and linked the levels with another known determinant of COVID-19-related mortality, the researchers also noted.

A review of the literature also showed that vaccines against HIV, malaria, and pertussis also induce the production of IgG4.

“In sum, COVID-19 epidemiological studies cited in our work plus the failure of HIV, Malaria, and Pertussis vaccines constitute irrefutable evidence demonstrating that an increase in IgG4 levels impairs immune responses,” Alberto Rubio Casillas, a researcher with the biology laboratory at the University of Guadalajara in Mexico and one of the authors of the new paper, told The Epoch Times via email.

The paper was published by the journal Vaccines in May.

Pfizer and Moderna officials didn’t respond to requests for comment.

Both companies utilize messenger RNA (mRNA) technology in their vaccines.

Dr. Robert Malone, who helped invent the technology, said the paper illustrates why he’s been warning about the negative effects of repeated vaccination.

“I warned that more jabs can result in what’s called high zone tolerance, of which the switch to IgG4 is one of the mechanisms. And now we have data that clearly demonstrate that’s occurring in the case of this as well as some other vaccines,” Malone, who wasn’t involved with the study, told The Epoch Times.

So it’s basically validating that this rush to administer and re-administer without having solid data to back those decisions was highly counterproductive and appears to have resulted in a cohort of people that are actually more susceptible to the disease.”

Possible Problems

The weakened immune systems brought about by repeated vaccination could lead to serious problems, including cancer, the researchers said.

Read more here...

Tyler Durden Sat, 06/03/2023 - 22:30

Read More

Continue Reading


Study Falsely Linking Hydroxychloroquine To Increased Deaths Frequently Cited Even After Retraction

Study Falsely Linking Hydroxychloroquine To Increased Deaths Frequently Cited Even After Retraction

Authored by Jessie Zhang via Thje Epoch…



Study Falsely Linking Hydroxychloroquine To Increased Deaths Frequently Cited Even After Retraction

Authored by Jessie Zhang via Thje Epoch Times (emphasis ours),

An Australian and Swedish investigation has found that among the hundreds of COVID-19 research papers that have been withdrawn, a retracted study linking the drug hydroxychloroquine to increased mortality was the most cited paper.

Hydroxychloroquine sulphate tablets. (Memories Over Mocha/Shutterstock)

With 1,360 citations at the time of data extraction, researchers in the field were still referring to the paper “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis” long after it was retracted.

Authors of the analysis involving the University of Wollongong, Linköping University, and Western Sydney Local Health District wrote (pdf) that “most researchers who cite retracted research do not identify that the paper is retracted, even when submitting long after the paper has been withdrawn.”

“This has serious implications for the reliability of published research and the academic literature, which need to be addressed,” they said.

Retraction is the final safeguard against academic error and misconduct, and thus a cornerstone of the entire process of knowledge generation.”

Scientists Question Findings

Over 100 medical professionals wrote an open letter, raising ten major issues with the paper.

These included the fact that there was “no ethics review” and “unusually small reported variances in baseline variables, interventions and outcomes,” as well as “no mention of the countries or hospitals that contributed to the data source and no acknowledgments to their contributions.”

A bottle of Hydroxychloroquine at the Medicine Shoppe in Wilkes-Barre, Pa on March 31, 2020. Some politicians and doctors were sparring over whether to use hydroxychloroquine against the new coronavirus, with many scientists saying the evidence is too thin to recommend it yet. (Mark Moran/The Citizens’ Voice via AP)

Other concerns were that the average daily doses of hydroxychloroquine were higher than the FDA-recommended amounts, which would present skewed results.

They also found that the data that was reportedly from Australian patients did not seem to match data from the Australian government.

Eventually, the study led the World Health Organization to temporarily suspend the trial of hydroxychloroquine on COVID-19 patients and to the UK regulatory body, MHRA, requesting the temporary pause of recruitment into all hydroxychloroquine trials in the UK.

France also changed its national recommendation of the drug in COVID-19 treatments and halted all trials.

Currently, a total of 337 research papers on COVID-19 have been retracted, according to Retraction Watch.

Further retractions are expected as the investigation of proceeds.

Tyler Durden Sat, 06/03/2023 - 17:30

Read More

Continue Reading


Complying, Not Defying: Twitter And The EU Censorship Code

Complying, Not Defying: Twitter And The EU Censorship Code

Authored by ‘Robert Kogon’ via The Brownstone Institute,

So, word has it that…



Complying, Not Defying: Twitter And The EU Censorship Code

Authored by 'Robert Kogon' via The Brownstone Institute,

So, word has it that Twitter has withdrawn from the EU’s Code of Practice on Disinformation, a fact that appears only to be known thanks to a couple of pissy tweets from EU officials. I cannot help but wonder if this is not finally Elon Musk’s response to the question I asked in my article here several weeks ago: namely, how can a self-styled “free-speech absolutist” be part of a “Permanent Task-Force on Disinformation” that is precisely a creation of the EU’s Code?

But does it matter? The answer is no. The withdrawal of Twitter’s signature from the Code is a highly theatrical, but essentially empty gesture, which will undoubtedly serve to shore up Musk’s free speech bad-boy bona fides, but has virtually no practical consequences. 

This is because: (1) as I have discussed in various articles (for instance, here and here), the effect of the EU’s Digital Services Act (DSA) is to render the hitherto ostensibly voluntary commitments undertaken in the Code obligatory for all so-called Very Large Online Platforms (VLOPs) and (2) as discussed here, the European Commission just designated a whole series of entities as VLOPs that were never signatories of the Code.

Twitter is thus in no different a position than Amazon, Apple and Wikipedia, none of which were ever signatories of the Code, but all of which will be expected by the EU to comply with its censorship requirements on the pain of ruinous fines. 

As EU officials like to put it, the DSA transformed the “code of practice” into a code of conduct: i.e. you had better do it or else.

Compliance is thus not a matter of a signature. The proof of the pudding is in the eating. And the fact of the matter is that Musk and Twitter are complying with the EU’s censorship requirements. Much of the programming that has gone into the Twitter algorithm is obviously designed for this very purpose.

What, for instance, are the below lines of code?

They are “safety labels” that have been included in the algorithm to restrict the visibility of alleged “misinformation.” Furthermore – leaving aside the handy “generic misinfo” catch-all – the general categories of “misinformation” used exactly mirror the main areas of concern targeted by the EU in its efforts to “regulate” online speech: “medical misinfo” in the context of the COVID-19 pandemic, “civic misinfo” in the context of issues of electoral integrity, and “crisis misinfo” in the context of the war in Ukraine.

Indeed, as Elon Musk and his lawyers certainly know, the final version of the DSA includes a “crisis response mechanism,” (Art. 36) which is clearly modeled on the European Commission’s initially ad hoc response to the Ukraine crisis and which requires platforms to take special measures to mitigate crisis-related “misinformation.” 

In its January submission to the EU (see reports archive here), in the section devoted precisely to its efforts to combat Ukraine-war-related “misinformation,” Twitter writes (pp. 70-71): 

“We … use a combination of technology and human review to proactively identify misleading information. More than 65% of violative content is surfaced by our automated systems, and the majority of remaining content we enforce on is surfaced through regular monitoring by our internal teams and our work with trusted partners.”

How is this not compliance? Or at least a very vigorous effort to achieve it? And the methodology outlined is presumably used to “enforce on” other types of “mis-“ or “disinformation” as well.

Finally, what is the below notice, which many Twitter users recently received informing them that they are not eligible to participate in Twitter Ads because their account as such has been labeled “organic misinformation?”

Why in the world would Twitter turn away advertising business? The answer is simple and straightforward: because none other than the EU’s Code of Practice on Disinformation requires it to do so in connection with the so-called “demonetization of disinformation.” 

Thus, section II(d-f) of the Code reads:

(d) The Signatories recognise the need to combat the dissemination of harmful Disinformation via advertising messages and services.

(e) Relevant Signatories recognise the need to take granular and tailored action to address Disinformation risks linked to the distribution of online advertising. Actions will be applicable to all online advertising.

(f) Relevant Signatories recognise the importance of implementing policies and processes not to accept remuneration from Disinformation actors, or otherwise promote such accounts and websites.

So, in short, vis-à-vis the EU and its Code, Twitter is complying, not defying. Removing Twitter’s signature from the Code when its signature is no longer required on the Code anyway is not defiance. Among other things, not labeling content and/or users as “misinformation,” not restricting the visibility of content and/or users so labeled, and accepting advertising from whomever has the money to pay would be defiance.

But the EU’s response to such defiance would undoubtedly be something more than tweets. It would be the mobilization of the entire punitive arsenal contained in the DSA and, in particular, the threat or application of the DSA fines of 6 percent of the company’s global turnover.

It is not enough to (symbolically) withdraw from the Code of Practice to defy the EU. Defying the EU would require Twitter to withdraw from the EU altogether.

Tyler Durden Sat, 06/03/2023 - 10:30

Read More

Continue Reading